A Randomized Controlled Study in Newly Diagnosed Severe Aplastic Anemia Patients Receiving Antithymocyte Globulin (ATG), Cyclosporin A, with or without Granulocyte Colony Stimulating Factor (G-CSF)

European Group Blood and Marrow Transplantation0 个研究点目标入组 340 人开始时间: 2005年10月21日最近更新: 2015年1月13日

试验速览

暂无简介。

•1. Severe or very severe aplastic anaemia
•2. Less than 6 months from diagnosis of severe aplastic anaemia by bone marrow biopsy
•3. For patients in the UK and in Germany there are minimum age restrictions: 16 and 18 years respectively

•1. Eligibility for a human leukocyte antigen (HLA) matched sibling donor transplant
•2. Prior therapy with ATG
•3. Cyclosporin A <4 weeks before enrollment
•4. Treatment with G-CSF <2 weeks before enrollment
•5. Other growth factors <4 weeks before enrollment
•6. Diagnosis of Fanconi anaemia, dyskeratosis congenita or congenital bone marrow failure syndrome
•7. Evidence of myelodysplastic disease
•8. Diagnosis or previous history of carcinoma (except local cervical, basal cell, squamous cells, or melanoma)
•9. Subjects who have infection, hepatic, renal cardiac, metabolic or other concurrent diseases of such severity that death is imminent
•10. Pregnant or breast feeding females

发起方

European Group Blood and Marrow Transplantation